Cadrenal Therapeutics, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Cadrenal reported Q2 2026 net loss of $3.3M on $3.3M operating expenses. The company raised ~$3.0M gross proceeds from a private placement (with potential $5.8M additional from warrant exercise), leaving $2.4M cash on hand as of early August 2026—sufficient to fund operations through Q1 2027 only. Cadrenal launched a structured strategic partnering process to out-license CAD-1005, frunexian, and tecarfarin; presented late-breaking Phase 2 CAD-1005 data at ISTH showing >25% absolute reduction in thrombotic events; and signed an agreement with a firm experienced in securing >$500M in non-dilutive funding.
Why this rating
Partnering process + positive Phase 2 data + capital raise partially offset severe cash burn and near-term funding crisis. Real but contingent on deal execution.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.